Stockreport

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 [Yahoo! Finance]

Kronos Bio, Inc.  (KRON) 
PDF SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address [Read more]